Illumigen Biosciences, Inc.

Seattle, WA 98134
http://www.illumigen.com
9 Employees

SBIR Award Summary

Total Number of Awards 7
Total Value of Awards $2.09MM
First Award Date 04/01/01
Most Recent Award Date 09/01/03

Key Personnel

Last Name Name Awards Contact
Iadonato Dr. Shawn P. Iadonato 3 Message
Magness Charles L Magness 3
Rosenberg Gary Rosenberg 1

7 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/01/03 - 08/31/04

DESCRIPTION (provided by applicant): Expression of the gene encoding phospholipase A2 group 13 (PLA2G13) was found to be significantly upregulated in hepatocellular carcinoma (HCC) tissue relative to adjacent nonmalignant liver. In a search of public gene expression databases, only one cDNA library was found to contain the sequence encoding PLA2...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/03 - 10/31/04

DESCRIPTION (provided by applicant): Phase II development of an automated DNA sequence variation analysis software package is proposed. The software analyzes diploid DNA sequencing and mixed methylation analysis samples from phenotypically stratified patient groups. The software package detects essenti...

Phase 2 SBIR

Agency: Chemical and Biological Defense Program
Topic: C02-100
Budget: 04/14/03 - 04/14/05

This Phase II continuation of ongoing research aims to extend our existing database of human molecular response to infection with biological pathogens. We will compile gene expression changes that are predictive of infection with a larger variety of bacterial and viral pathogens. The ultimate goal is to perform analyses that may form the basis...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-01-52
Budget: 04/01/03 - 07/31/04

DESCRIPTION (provided by applicant): Illumigen is pursuing an alternative genetics-driven approach to drug discovery that relies on the identification of mutations associated with health rather than disease. Beneficial or health-inducing mutations, like most disease-causing mutations, are expected to negatively impact gene function in a way tha...

Phase 1 SBIR

Agency: Chemical and Biological Defense Program
Topic: CBD02-100
Budget: 08/08/02 - 04/14/05

This proposal is in response to a request for applications from the Chemical and Biological Defense program. Illumigen Biosciences Inc. proposes a series of experiments to explore the utility of using DNA microarrays as a tool to detect gene expression changes that are diagnostic of exposure to biological agents. The ultimate goal of a combined ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 05/01/02 - 04/30/03

DESCRIPTION (provided by applicant): Phase II development of an automated DNA sequence variation analysis software package is proposed. The software analyzes diploid DNA sequencing and mixed methylation analysis samples from phenotypically stratified patient groups. The software package detects essenti...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 04/01/01 - 09/30/01

Development of an automated DNA sequence variation analysis software and data management package is proposed. The software is aimed at analyzing diploid sequencing and methylation analysis samples from patients in a study population that have been stratified by some defining criteria or phenotype in relation to a disease of interest. The goal of...